Abstract 84P
Background
Several studies showed that sex is a biological variable that influence immune response in several types of solid tumors; however, there is scarce information in hematological malignancies. In this work, we evaluate differences in immune cells compositions and immune response of multiple myeloma between sexes.
Methods
We conducted a computational biology study using transcriptomic data obtained from bone marrow aspiration collected from untreated multiple myeloma patients under the MMRF-COMMPASS protocol (study accession phs000748). Data was pre-processed and the expression levels were normalized to TPM (transcript per million). To evaluate differences in immune cells compositions, we quantified the immune cell in the tumor microenvironment with the analytic platform CIBERSORT. Differences in activated immune pathways was evaluated with the gene set enrichment analysis (GSEA). Pre-processed counts were normalized to TMM (trimmed mean of M-values) and GSEA was performed using the GSEA java desktop application (v4.3.2). In both analysis, patterns of immune gene sets and the immune cell composition were compared between tumors from female vs. male patients. A p<0.05 and a FDR<25% were considered statistically significant for GSEA analysis, while a p<0.05 and a FDR<0.05 6.1x10-5 was considered statistically significant for CIBERSORT analysis.
Results
Overall, 451 males and 313 female patients were included. We detected in samples from female patients an enrichment of dendritic cells activated (p=0.0023, FDR=0,0257) and NK cells activated (p=0.0059, FDR=0,0326). In contrast, we observed in male patients an enrichment of monocytes (p=6.10x 10 -5 , FDR=0,0013) and macrophages M1(p=0,0050, FDR=0,0326). The GSEA analysis revealed an overregulation of natural killer cell degranulation (p=0.007, FDR=0.21624), positive regulation of type I interferon mediated signaling pathway (p<0.0001, FDR=0.23946), and regulation of natural killer cell proliferation (p=0.01, FDR=0.2495).
Conclusions
The computational analysis showed some differences in the immune microenvironment, between sexes in multiple myeloma. Studies about the influence of these differences in the clinical outcomes of patients should be evaluated.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
56P - SLC34A2-ROS1 L2026M+G2032R confers resistance to ROS1 tyrosine kinase inhibitors in Ba/F3 cells through a reduced ATP binding pocket volume
Presenter: Christa Dijkhuizen
Session: Poster session 09
57P - Metastasis organotropism: Unveiling associated proteins using network biology
Presenter: Margarida Carrolo
Session: Poster session 09
59P - Correlation of tumor microenvironment signature in advanced stage non-small cell lung cancer with EGFR mutation who received EGFR-TKIs
Presenter: Chaiyapong Ngamchokwathana
Session: Poster session 09
60P - Establishment and characterization of a novel lung adenocarcinoma cell line HX-JCJ harboring MET ex14 skipping mutation
Presenter: Xuejin Ou
Session: Poster session 09
61P - Next generation sequencing and its clinical utility in advanced cancer: Single institute experience from low-middle income country
Presenter: Amit Badola
Session: Poster session 09
62P - Prebiotics modulate gut microbiota-mediated T cell immunity to enhance sintilimab inhibition of lung cancer
Presenter: QIN YAN
Session: Poster session 09
63P - Addition of human chorionic gonadotropin to the current standard mobilization approach with granulocyte-colony stimulating factor increases overall survival in a murine model of peripheral blood stem cell transplantation: Are we far enough for therapy?
Presenter: Andrei Cismaru
Session: Poster session 09
64P - Developing novel therapeutics for bladder cancer leveraging drosophila models
Presenter: Takuya Moriguchi
Session: Poster session 09
65P - Ionizing radiation induces vascular smooth muscle cell senescence through activating NF-κB-CTCF-p16 pathway
Presenter: xuefeng zheng
Session: Poster session 09
66P - Exploring the radiobiology and dosimetry of targeted alpha therapy as a tool to optimize its clinical application: A preclinical study
Presenter: Maria Filomena Botelho
Session: Poster session 09